Cawthorne, Chris - University of Hull - Department of Biology / Biomedical Sciences

个人简介

1996-2000 BSc (Hons) Molecular Biology, University of Hertfordshire 2001-2005 PhD Molecular Pharmacology, Cellular and Molecular Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester 2006-2012 Postdoctoral Researcher, PET Oncology Group, Wolfson Molecular Imaging Centre, University of Manchester 2013-present Lecturer in Molecular Imaging, University of Hull

研究领域

The overall aim of my research is to improve the treatment of cancer through the application of molecular imaging, mainly using positron emission tomography (PET) and single-photon emission computed tomography (SPECT). This involves the evaluation of novel and existing radionuclide imaging probes for use as biomarkers in cancer therapy using a range of in vitro and in vivo tumour models, with a focus on quantitation and translation to the clinic. Medical imaging is a cornerstone of patient management in oncology, allowing assessment of the whole tumour mass, and indeed the whole disease burden in the patient, in a non-invasive or minimally invasive manner. Molecular imaging using positron emission tomography (PET) and single-photon emission tomography (SPET) can provide quantitative information on a specific tumour target or a process of interest or the distribution of a therapeutic agent, depending on the nature of the probe. This has the potential to provide information on whether or not a patient is suitable for treatment with a novel targeted therapy, whether or not a drug reaches the site of action and exerts the expected pharmacological effect there, and whether this results in a therapeutic response. Monitoring therapy response is increasingly important for both chemotherapy and radiotherapy and PET has the potential to do this soon after the beginning of treatment; it may also allow the detection of resistant disease. I also have a strong interest in the development of new preclinical models of cancer that better mimic the clinical situation, and the development and use of advanced reconstruction/modelling techniques to obtain quantitative data. Current research projects include: Validation of novel PET imaging probes for C-X-C chemokine receptor type 4 (CXCR4) Development of novel PET imaging probes for αVβ6 Development of Nanoparticles for imaging and drug delivery Development of novel multimodality imaging agents for assessment of mitochondrial membrane potential Validation of novel and existing imaging probes for adaptive radiotherapy Development of methods for PET radiotracer quantitation using microfluidics Development of organotypic tumour models for imaging and therapy

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Entract GM, Bryden F, Domarkas J, Savoie H, Allott L, Archibald SJ, Cawthorne C, Boyle RW. “Development of PDT/PET Theranostics: Synthesis and Biological Evaluation of an 18F-Radiolabelled Water-Soluble Porphyrin”. Molecular Pharmaceutics 2015 Nov 23 [Epub ahead of print] Burke BP, Baghdadi N, Kownacka AE, Nigam S, Clemente GS, Al-Yasiry MM, Domarkas J, Lorch M, Pickles M, Gibbs P, Tripier R, Cawthorne C, Archibald SJ. “Chelator free gallium-68 radiolabelling of silica coated iron oxide nanorods via surface interactions.” Nanoscale 2015 Sep 28;7(36):14889-96 Poty S, Désogère P, Goze C, Boschetti F, D'huys T, Schols D, Cawthorne C, Archibald SJ, Maëcke HR, Denat F. “New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities. Dalton Transactions 2015 2015 Mar 21;44(11):5004-16. Kadirvel M, Fairclough M, Cawthorne C, Rowling EJ, Babur M, McMahon A, Birkket P, Smigova A, Freeman S, Williams KJ, Brown G.l. “Novel synthesis of the apoptotic probe [18F]-ML10” Bioorganic and Medicinal Chemistry. 2014 Jan; 22(1):341-9 Cawthorne C, Burrows N, Gieling RG, Morrow CJ, Forster D, Gregory J, Radigois M, Smigova A, Babur M, Simpson K, Hodgkinson C, Brown G, McMahon A, Dive C, Hiscock D, Wilson I, Williams KJ. ‘[18F]-FLT Positron Emission Tomography can be used to image the response of sensitive tumours to PI3-Kinase inhibition with the novel agent GDC-0941’ Molecular Cancer Therapeutics. 2013 May; 12(5):819-28 Simpson K, Cawthorne C, Zhou C, Hodgkinson CL, Walker MJ, Trapani F, Kadirvel M, Brown G, Dawson MJ, MacFarlane M, Williams KJ, Whetton AD, Dive C. ‘A caspase-3 ‘death-switch’ in colorectal cancer cells for induced and synchronous tumour apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers’. Cell Death and Disease. May 2; 44: e613. doi: 10.1038/cddis.2013.13 Boutin H, Prenant C, Maroy Rm Galea J, Greehalgh AD, Smigova A, Cawthorne C, Julyan P, Wilkinson SM, Banister SD, Brown G, Herholz K, Kassiou M, Rothwell NJ.’[18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in rats.’ PLoS One 2013: 8(2):e56441. Doi:10.1371/journal.pone.0056441 Cawthorne C, Prenant C, Smigova A, Julyan P, Maroy R, Herholz K, Rothwell N, Boutin H. ‘Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [18F]-IL1RA and PET imaging in rats.’ British Journal of Pharmacology. 2011 Feb; 162(3):659-72 Prenant C, Cawthorne C Rothwell N, Boutin H. ‘Radiolabeling with fluorine-18 of a protein, interleukin-1 receptor antagonist. Appl Radiat Isot. 2010 Sep; 68(9):1721-7 Lunt SJ, Cawthorne C, Ali M, Telfer BA, Babur M, Smigova A, Julyan PJ, Price PM, Stratford IJ, Bloomer WD, Papadopoulou MV, Williams KJ. ‘The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy’ British Journal of Cancer. 2010 Aug;99(3):459-63.